On or around 01/02/2018 (Court's order of dismissal)
Filing Date: October 26, 2017
According to the Complaint, XBiotech is a clinical-stage biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal mmunization or otherwise engineered. The Company concentrates on developing MABp1 (also known as Xilonix™, CA-18C3, CV-18C3, RA-18C3, T2-18C3 and Hutruo) (hereafter referred to as “Xilonix”), a therapeutic antibody which is supposed to neutralize interleukin-1 alpha (IL-1a). IL-1a is a proinflammatory protein produced by leukocytes and other cells, where it plays a key role in inflammation. When unchecked, inflammation can contribute to the development and progression of a variety of different diseases such as cancer, vascular disease, inflammatory skin disease, and diabetes.
The Complaint alleges that throughout the Class Period, Defendants publicly issued materially false and misleading statements and omitted material facts necessary to make Defendants' statements not false or misleading, causing XBiotech’s securities to be artificially inflated.
This case was voluntarily dismissed on December 26, 2017.
Company & Securities Information
Defendant: XBiotech, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: XBIT
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.